The latest announcement is out from Cingulate Inc ( (CING) ).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cingulate Inc. has secured a $5 million financing arrangement through an unsecured promissory note with Streeterville Capital, LLC. The funds will support clinical, manufacturing, and regulatory activities, extending the company’s cash runway into the fourth quarter of 2025. This financial move strategically positions Cingulate to advance its drug pipeline, including the anticipated mid-2025 NDA filing for CTx-1301, potentially enhancing its market competitiveness and investor appeal.
More about Cingulate Inc
Cingulate Inc. is a biopharmaceutical company leveraging its proprietary Precision Timed Release (PTR) drug delivery technology to develop a pipeline of next-generation pharmaceutical products. The company focuses on improving treatments for frequently diagnosed conditions with suboptimal outcomes, initially targeting ADHD and exploring further applications in areas such as anxiety disorders. Based in Kansas City, Cingulate is dedicated to enhancing patient care through innovative therapeutic solutions.
YTD Price Performance: -95.53%
Average Trading Volume: 133,127
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.17M
See more data about CING stock on TipRanks’ Stock Analysis page.